Beam Therapeutics Secures $135 Million in Series B Financing to Advance Base Editing Platform and Expand Pipeline of Precision Genetic Medicines
Cambridge, Mass. – Beam Therapeutics, a biotechnology company developing precision...
The human genome is made up of billions of nucleobases, or “bases,” represented by the letters A, G, T, and C. Beam’s base editing technology can precisely target and make specific edits to a single base in DNA or RNA, without cutting or disrupting the gene. Base editors have the potential to repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes. Beam is committed to developing base editors as a new class of precision genetic medicines that can treat or cure diseases affecting patients’ lives.
Starting with our founders and funders, we’re building a world-class team to develop precision genetic medicines through DNA and RNA base editing. Join us.
Beam is seeking a highly energetic individual who has technical knowledge in Cell & Gene Therapy to join the PharmaceuticalRead More
We are seeking an innovative and motivated Scientist with deep experience in molecular biology, and protein biochemistry, ideally of CRISPRRead More
Beam is looking for a highly motivated and experienced Research Associate to support our RNA editing &Novel CRISPR nucleases platform.Read More
26 Landsdowne Street
Cambridge, MA 02139